Agreements cover territories within the Pacific Northwest, Southeast and Midwest
Reports growing interest following successful showing at The SOAP 50th Annual Meeting
Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced it has signed agreements with three additional independent distributors for its CompuFlo® Epidural System covering territories within the Pacific Northwest, Southeast and additional coverage in the Midwest. The company also reported on interest generated in the CompuFlo® Epidural System at The Society for Obstetric Anesthesia and Perinatology (SOAP) 50th Annual Meeting that was held in Miami from May 9-13.
Sharon Smith, Executive Vice President of Global Sales and Marketing of Milestone Scientific, commented, “We are encouraged by the growing interest in the CompuFlo® Epidural System, as evidenced by the addition of these three latest independent distributors, which provide us coverage in the Pacific Northwest and Southeast, as well as deeper penetration within the Midwest. In addition to these distributors, we are in active discussions with many others nationwide. This recent success reflects our new decentralized sales strategy, whereby we are targeting independent distributors with existing physician and hospital relationships within their respective territories and clinical specialties. We were also pleased with the favorable response the CompuFlo® Epidural System generated at the SOAP meeting. We look forward to following up with the anesthesia providers we met that desire a tool that objectively identifies the epidural space and aides in discriminating between true and false loss of resistance.”
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone’s computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone’s proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report for the year ended December 31, 2017. The forward looking statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: [email protected]
Tel: 212-671-1020
